PMID- 36626639
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20240116
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Print)
IS  - 0270-9139 (Linking)
VI  - 78
IP  - 5
DP  - 2023 Nov 1
TI  - Metabolic reprogramming and its clinical implication for liver cancer.
PG  - 1602-1624
LID - 10.1097/HEP.0000000000000005 [doi]
AB  - Cancer cells often encounter hypoxic and hypo-nutrient conditions, which force 
      them to make adaptive changes to meet their high demands for energy and various 
      biomaterials for biomass synthesis. As a result, enhanced catabolism (breakdown 
      of macromolecules for energy production) and anabolism (macromolecule synthesis 
      from bio-precursors) are induced in cancer. This phenomenon is called "metabolic 
      reprogramming," a cancer hallmark contributing to cancer development, metastasis, 
      and drug resistance. HCC and cholangiocarcinoma (CCA) are 2 different liver 
      cancers with high intertumoral heterogeneity in terms of etiologies, mutational 
      landscapes, transcriptomes, and histological representations. In agreement, 
      metabolism in HCC or CCA is remarkably heterogeneous, although changes in the 
      glycolytic pathways and an increase in the generation of lactate (the Warburg 
      effect) have been frequently detected in those tumors. For example, HCC tumors 
      with activated beta-catenin are addicted to fatty acid catabolism, whereas HCC 
      tumors derived from fatty liver avoid using fatty acids. In this review, we 
      describe common metabolic alterations in HCC and CCA as well as metabolic 
      features unique for their subsets. We discuss metabolism of NAFLD as well, 
      because NAFLD will likely become a leading etiology of liver cancer in the coming 
      years due to the obesity epidemic in the Western world. Furthermore, we outline 
      the clinical implication of liver cancer metabolism and highlight the computation 
      and systems biology approaches, such as genome-wide metabolic models, as a 
      valuable tool allowing us to identify therapeutic targets and develop 
      personalized treatments for liver cancer patients.
CI  - Copyright (c) 2023 American Association for the Study of Liver Diseases.
FAU - Yang, Flora
AU  - Yang F
AUID- ORCID: 0000-0002-3934-7437
AD  - BA/MD Joint Admission Scholars Program, University of Minnesota, Minneapolis, 
      Minnesota.
FAU - Hilakivi-Clarke, Leena
AU  - Hilakivi-Clarke L
AUID- ORCID: 0000-0002-7052-6513
AD  - Food Science and Nutrition Section, The Hormel Institute, University of 
      Minnesota, Austin, Minnesota.
FAU - Shaha, Aurpita
AU  - Shaha A
AUID- ORCID: 0000-0001-5681-903
AD  - Tumor Microenvironment and Metastasis Section, the Hormel Institute, University 
      of Minnesota, Austin, Minnesota.
FAU - Wang, Yuanguo
AU  - Wang Y
AUID- ORCID: 0000-0003-4752-9908
AD  - Tumor Microenvironment and Metastasis Section, the Hormel Institute, University 
      of Minnesota, Austin, Minnesota.
FAU - Wang, Xianghu
AU  - Wang X
AUID- ORCID: 0000-0001-5515-0514
AD  - Tumor Microenvironment and Metastasis Section, the Hormel Institute, University 
      of Minnesota, Austin, Minnesota.
FAU - Deng, Yibin
AU  - Deng Y
AUID- ORCID: 0000-0001-5711-3565
AD  - Department of Urology, Masonic Cancer Center, The University of Minnesota Medical 
      School, Minneapolis, Minnesota.
FAU - Lai, Jinping
AU  - Lai J
AUID- ORCID: 0000-0002-4234-5096
AD  - Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento 
      Medical Center, Sacramento, California.
FAU - Kang, Ningling
AU  - Kang N
AUID- ORCID: 0000-0002-4565-7976
AD  - Tumor Microenvironment and Metastasis Section, the Hormel Institute, University 
      of Minnesota, Austin, Minnesota.
LA  - eng
GR  - P50 CA210964/CA/NCI NIH HHS/United States
GR  - R01 CA160069/CA/NCI NIH HHS/United States
GR  - R21 CA256428/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20230103
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
SB  - IM
MH  - Humans
MH  - *Liver Neoplasms/metabolism
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Non-alcoholic Fatty Liver Disease
MH  - *Bile Duct Neoplasms/pathology
MH  - Bile Ducts, Intrahepatic/pathology
PMC - PMC10315435
MID - NIHMS1903914
COIS- CONFLICT OF INTEREST Nothing to report.
EDAT- 2023/01/11 06:00
MHDA- 2023/10/23 00:42
PMCR- 2023/11/01
CRDT- 2023/01/10 14:51
PHST- 2022/05/19 00:00 [received]
PHST- 2022/09/28 00:00 [accepted]
PHST- 2023/10/23 00:42 [medline]
PHST- 2023/01/11 06:00 [pubmed]
PHST- 2023/01/10 14:51 [entrez]
PHST- 2023/11/01 00:00 [pmc-release]
AID - 01515467-202311000-00023 [pii]
AID - 10.1097/HEP.0000000000000005 [doi]
PST - ppublish
SO  - Hepatology. 2023 Nov 1;78(5):1602-1624. doi: 10.1097/HEP.0000000000000005. Epub 
      2023 Jan 3.